When: Positive MACD crossover with histogram > 0

Then: Momentum confirmation signal

HOLD

• Golden cross typically occurs within 2-6 weeks given 50 SMA at 129.48 versus 200 SMA at 130.92 (1.4-point gap)
• RSI at 53 with MACD histogram at minus 0.01 represents absence of signal, not a sell signal; lack of oversold during June 120.69 capitulation indicates accumulation
• PEG of 2.14 with 2.46% dividend yield and 5.9% FCF yield is not expensive for defensive pharma; beta of 0.336 warrants yield/downside protection lens, not growth framework
• PrEP sales doubled to approximately $1 billion quarterly run rate; FY27 PrEP revenue could reach $4 billion-plus versus $165 billion market cap; persistence rates above 70 percent per Bank of America support multi-year re-rating
• Q2 FCF of $3.4 billion generated while spending $11.2 billion on acquisition; net debt to EBITDA of 1.2x indicates investment-grade capacity; reported EBITDA of $14.8 billion versus $23 billion net debt provides substantial covenant headroom
• Total shareholder yield of 8.4 percent acts as a real floor; trimming at 133 (Bollinger midpoint at 128-136) surrenders half the dividend income stream before technical repair completes
• Low beta dividend-paying pharma historically performs positively during risk-off events; 2.46% dividend with 5.9% FCF yield improves relative attractiveness when yields rise on inflation fears
• Trim introduces risk rather than mitigates it; fundamental report supports HOLD, technical report says constructive unconfirmed recovery with HOLD, sentiment report mixed with slight bullish tilt
• Conservative move is to treat 130.92 to 129.48 zone as opportunity to scale in with hard stop below 128.18; if stop triggers, defined loss is approximately 3.5%; if technicals confirm with golden cross plus PrEP beat, upside is 5-10 percent to 140 zone
• SELL is correct only if time horizon is weeks; HOLD with defined add zone is correct if time horizon is quarters; risk discipline favors quarters

→ vs aggressive: Death cross argument mischaracterizes structural damage; 1.4-point gap between 50 SMA (129.48) and 200 SMA (130.92) on a $133 stock is a rounding error, not bear trend confirmation

→ vs aggressive: RSI 53 interpretation is backwards; neutral RSI after 20-point round trip from 155 to 120 recovering to 133 is equilibrium, not coiled spring pointing lower; coiled spring would show RSI in 40s with negative MACD divergence

→ vs aggressive: PEG of 2.14 framework only works for high-beta growth names; for beta 0.336 with 8.4% total shareholder yield and 2.4x FCF coverage, the correct lens is yield and downside protection, not PEG; tech valuation applied to regulated cash flow business

→ vs aggressive: Yeztugo PrEP pricing-in claim is a guess, not analysis; PrEP doubled to $1 billion quarterly run rate in single quarter with FY27 potential $4 billion-plus; PrEP alone is not fully valued at $165 billion market cap

→ vs aggressive: Balance sheet characterized as catastrophic is misleading; $11.2 billion acquisition spend with simultaneous $3.4 billion Q2 FCF generation is investment, not cash burning; 1.2x net debt to EBITDA is investment grade with capacity

→ vs aggressive: Risk reward framing on trim is incorrect; entry framing at 140.60 with stop at 128.18 ignores that trim executes at current 133, not entry price; cost of being wrong is missed rally, not just stop-out

→ vs aggressive: Macro risk-off argument is empirically wrong; low beta dividend-paying pharma historically performs positively during risk-off; cross-asset relationship is inverted

→ vs neutral: Fundamental report supports HOLD clearly, technical report says constructive unconfirmed recovery with HOLD, sentiment report mixed with slight bullish tilt; trim to underweight is the position that introduces risk

REDUCE (partial trim to 70-75% of benchmark with re-entry trigger at 135.88 and stop at 128.18)

• 50 SMA at 129.48 versus 200 SMA at 130.92 is a 1.44 point (1.1%) gap—not catastrophic as aggressive claims
• RSI at 53 represents equilibrium, not negative momentum; MACD at 0.66 vs signal 0.67 with histogram -0.01 is absence of momentum, not bearish momentum
• PEG of 2.14 at 13.5x forward earnings with 2-6% revenue growth is a yellow flag, not red or non-issue—GILD is fairly valued to mildly expensive
• Cash drop from 9.6B to 3.2B while funding 11.2B acquisition and generating 3.4B FCF is capital allocation, not balance sheet stress; net debt to EBITDA of 1.2x is investment grade
• Yeztugo is highest-leverage catalyst but one quarter of PrEP doubling from small base is insufficient data for multi-year rerating thesis
• Q2 12.6B in unusual items represents real integration risk to monitor; cannot be dismissed as accounting noise
• Trodelvy-Keytruda combo failure is genuine pipeline setback; aggressive is correct it shouldn't be dismissed as noise
• Macro effect is mildly negative (wash)—pharma holds better than cyclicals in risk-off but faces multiple compression from rising yields
• Accumulation narrative based on VWMA rising since July 10 is plausible but not proven; June 120.69 low could be stop hunt not capitulation
• Aggressive time horizon is weeks; conservative is quarters; prudent default is quarters for defensive pharma with 2.46% yield

→ vs aggressive: Death cross framing as 'structural catastrophe' is rhetorical overreach—the 1.1% gap carries no mechanical significance

→ vs aggressive: RSI 53 as 'coiled spring' is editorializing, not analysis; no divergence or lower momentum highs present

→ vs aggressive: Balance sheet 'stress' characterization is wrong—3.4B FCF generation alongside 11.2B acquisition is capital allocation in action

→ vs conservative: One month of constructive volume profile (VWAP rising since July 10) is insufficient to declare structural accumulation verdict

→ vs conservative: June 120.69 low as 'capitulation' is unconfirmed—could be stop hunt with unclear volume profile

→ vs conservative: Covenant headroom being 'real' doesn't mean write-down risk is overstated; integration risk and 12.6B unusual items require monitoring